Palantir is back on every screen this month, up 14.55% in a single week as retail traders pile back into the AI infrastructure trade that briefly wobbled in June.
Chinese judicial authorities are zeroing in on privacy coins and mixers.
Every feed you open right now has the same story: Dell Technologies (NYSE:DELL | DELL Price Prediction) is on a tear.
President Trump announced a new blockade and tolls on the Strait of Hormuz while investors remained jittery about tech stocks.
CEG adds nearly 10 GW of power capacity as AI, data centers, electrification and U.S. manufacturing drive electricity demand.
Extra Space Storage benefits from resilient demand, acquisitions and steady expansion, though new supply and higher debt remain headwinds.
CENT is improving efficiency through cost discipline, simplification and operational changes that support long-term profitability.
Q32 Bio (QTTB) shares doubled on Monday as the clinical-stage biotech firm announced positive 36-week topline data from Part B of its Phase 2a SIGNAL-AA trial. The trial that evaluated its anti-IL-7R antibody – “bempikibart” – in patients suffering from severe or very severe alopecia areata hit primary endpoints, demonstrating an impressive 40% SALT-20 response rate in its modified intent-to-treat cohort and displaying rare, off-drug clinical durability.
We once looked forward to Y2K. Now, it's Y2.3K (about 2030), also known as Quantum Advantage. That's when we expect quantum computers, like the ones Rigetti Computing (RGTI) is working on, to really be ready for prime time. Different companies are pursuing different roadmaps to get there. They're all working to maximize fidelity (accuracy) and also maximize speed, which makes fidelity harder to achieve. Within quantum, Rigetti's superconducting protocol makes it the group's speed demon. But it's behind on fidelity, at 91%. The near-term goal is 99.5%, and ultimately, it's aiming at 99.9%.
Agenus (Agenus Inc (NASDAQ:AGEN)) shares jumped about 100% on Monday after the biotechnology company announced an oversubscribed private placement of up to $340 million to support development of its botensilimab and balstilimab (BOT+BAL) immunotherapy combination in microsatellite-stable (MSS) colon cancer. The financing includes approximately $85 million in upfront gross proceeds, with an additional potential $255 million available through the full exercise of purchase warrants.
SK Hynix stock slumped in its first full day of U.S. trading as jitters continued to weigh on chip and memory stocks.
Arthur J. Gallagher expands its specialty insurance platform with the Med James acquisition, strengthening wholesale brokerage and MGA capabilities to support long-term growth.
Brown & Brown's commission growth, acquisitions and diversified operations support long-term expansion, though higher expenses, debt and international risks remain.
Renewed Middle East tensions tighten refined product markets, putting Valero Energy, Phillips 66 and Par Pacific in focus as refining margins climb.
NextEra (NEE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
APTIV PLC (APTV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ADM (ADM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Skyward (SKWD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Kinsale Capital Group (KNSL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Ametek (AME) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Virtu Financial (VIRT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Brookfield (BAM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CAE (CAE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Citizens Financial Group (CFG) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Commerce (CBSH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Cullen/Frost (CFR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Ategrity Specialty Insurance Company Holdings (ASIC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Chord Energy Corporation (CHRD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bolivia considers USDT payments alongside the boliviano and dollar while regulators prepare strict controls for banks and wallets.